Objectives: To investigate the clinical effectiveness and safety of fingolimod in the western
Iranian population. Methods: This study was performed as a prospective observational study …

Background: Fingolimod was the first oral therapy approved for treating relapsing-remitting
multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy …

Methods: In our trial, 50 patients resistant to conventional interferon therapy were assigned
to receive fingolimod 0.5 mg per day for 12 months. The number of Dadolinium (Gd) …

Background Fingolimod (Gilenya, Novartis pharmaceuticals) is the first oral disease-
modifying therapy for reducing the frequency of clinical relapses and delaying disability …

Background Fingolimod is an oral sphingosine-1-phosphate–receptor modulator, which has
demonstrated efficacy in clinical trials and has recently been approved for multiple sclerosis …

Aims The aim of the present meta‐analysis was to evaluate the efficacy and safety of
fingolimod in patients with relapsing multiple sclerosis (RMS). Methods PubMed, Embase …

Background Multiple sclerosis (MS) is a chronic disease characterized by demyelination,
glial activation and axonal degeneration in the central nervous system. At the present, there …

Introduction Fingolimod is an oral treatment for Relapsing-Remitting Multiple Sclerosis
(RRMS) with established efficacy in clinical trials. Post-marketing studies are important to …

Background Post-marketing studies are important to confirm what was established in clinical
trials, and to assess the intermediate and long-term efficacy and safety. Objective To assess …

Objective. The aim of this prospective observational multicenter postmarketing study was to
evaluate fingolimod efficacy in a real world clinical setting. Methods. One hundred forty-two …